NASDAQ:AIKI AIkido Pharma (AIKI) Stock Price, News & Analysis $3.16 -0.05 (-1.56%) As of 06/12/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About AIkido Pharma Stock (NASDAQ:AIKI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AIkido Pharma alerts:Sign Up Key Stats Today's Range$3.02▼$3.2350-Day Range$2.75▼$3.9152-Week Range$3.31▼$11.48Volume201,228 shsAverage Volume79,326 shsMarket Capitalization$17.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York. Read More Receive AIKI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AIKI Stock News HeadlinesCrypto, Real Estate, And More: The Lesser-Known 'Dealmakers' Behind Trump’s $5 Billion EmpireAugust 20, 2025 | msn.comHow an Obscure Firm Bet on the Trumps and Became Their Go-To DealmakerAugust 19, 2025 | msn.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.June 15 at 1:00 AM | Weiss Ratings (Ad)Don Jr. And Eric Trump Could Soon Sell $9.6 Million In Stock Granted For Brief Advisory Board Tenure, SEC Filing RevealsApril 26, 2025 | msn.comDon Jr. And Eric Trump Landed $3 Million In Stock For Joining Firm’s Advisory Board That Had Little Public Presence Before Their AppointmentApril 17, 2025 | msn.comTrump Sons Joined Dominari Holding’s Advisory Board–But There’s Little Public Record The Board Existed BeforehandMarch 7, 2025 | forbes.comDon Jr. and Eric Trump invest in small biotech turned fintech based in Trump Tower, sending stock skywardFebruary 12, 2025 | msn.comDominari Holdings Inc trading resumesFebruary 12, 2025 | markets.businessinsider.comSee More Headlines AIKI Stock Analysis - Frequently Asked Questions How have AIKI shares performed this year? AIkido Pharma's stock was trading at $4.95 at the start of the year. Since then, AIKI stock has decreased by 36.2% and is now trading at $3.16. When did AIkido Pharma's stock split? Shares of AIkido Pharma reverse split before market open on Tuesday, June 7th 2022.The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. Does AIkido Pharma have any subsidiaries? The following companies are subsidiaries of AIkido Pharma: Hoth Therapeutics. How do I buy shares of AIkido Pharma? Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AIkido Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIkido Pharma investors own include Atossa Genetics (ATOS), Bionano Genomics (BNGO), Ocugen (OCGN), Meta Platforms (META), Cineverse (CNVS) and Company Calendar Today6/15/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:AIKI CIK12239 Webwww.spherix.com Phone(112) 745-1374Fax703-992-9348Employees4Year Founded1967Profitability EPS (Trailing Twelve Months)($3.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-18.21% Return on Assets-16.94% Debt Debt-to-Equity RatioN/A Current Ratio29.54 Quick Ratio29.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$19.27 per share Price / Book0.16Miscellaneous Outstanding Shares5,485,000Free Float5,013,000Market Cap$17.33 million OptionableNot Optionable Beta0.93 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:AIKI) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIkido Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIkido Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
